Lexeo Therapeutics, Inc.
$2.96+$0.01 (+0.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $375.3M
- P/E
- -3.8x
- EV / EBITDA
- -3.3x
- Revenue
- $0.00
- ROCE
- -43.4%
Price chart
Technical chartScreen technicals →-66.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -2.0%
- 3M
- -41.5%
- 6M
- -42.2%
- 1Y
- -66.8%
- 5Y
- Short history
- A period is left blank when the price history is shorter than the period.
52-week range
Day change +$0.01 (+0.3%) from $2.95 to $2.96 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in LXEO, bought on each weekday since 2023.
News & filings
What Lexeo Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 100.0 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are more than ten times current liabilities.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Read moreShow less
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
- Sector
- Healthcare
- Shares outstanding
- 73.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $375.3M
- P/E
- -3.8x
- P/B
- 1.5x
- EV / EBITDA
- -3.3x
- 52-week high
- $10.63
- 52-week low
- $2.63
Profitability
- ROE
- -40.5%
- ROCE
- -43.4%
- ROIC
- -41.1%
- ROA
- -37.2%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$99.0M
Solvency
- Current ratio
- 11.21
- Debt / Equity
- 0.03
- Debt / Assets
- 0.03
- CFO / Net profit
- 0.99
- Cash / Market cap
- 16.8%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $654.0k | -$59.3M |
| FY2023 | $0.00 | -$66.4M |
| FY2024 | $0.00 | -$98.3M |
| FY2025 | $0.00 | -$100.0M |
Cash flows
FY2025: -$98.6M from operations, -$99.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$54.6M | -$55.5M |
| FY2023 | -$59.5M | -$59.7M |
| FY2024 | -$81.2M | -$81.6M |
| FY2025 | -$98.6M | -$99.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$97.7M
- Net profit
- -$100.0M
- Cash from operations
- -$98.6M
- Free cash flow
- -$99.0M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$97.7M | -$100.0M | -$99.0M | -40.5% | — | +1.7% |
Monthly returns
Month-by-month returns of LXEO across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $268.7M |
| Current assets | $188.4M |
| Non-current assets | $80.3M |
| Liabilities | $22.0M |
| Current liabilities | $16.8M |
| Non-current liabilities | $5.2M |
| Equity | $246.7M |
| Paid-in capital | $626.6M |
| Retained earnings | -$380.1M |
| Treasury stock | $20.0k |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; LXEO highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Lexeo Therapeutics, Inc., Compass Therapeutics, Inc., Benitec Biopharma Inc., Perspective Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc.LXEOthis company | $375.3M | -3.8x | 1.5x | -40.5% | -3.3x |
| OmniAb, Inc.OABI | $385.6M | -6.0x | 1.4x | -24.3% | -8.1x |
| Compass Therapeutics, Inc.CMPX | $383.6M | -5.8x | 1.9x | -33.8% | -5.1x |
| Benitec Biopharma Inc.BNTC | $379.6M | -10.0x | 3.9x | -39.0% | -6.8x |
| Viemed Healthcare, Inc.VMD | $377.2M | 25.3x | 2.7x | 10.6% | 7.4x |
| CapsoVision, Inc.CV | $376.7M | -14.9x | 28.4x | -190.9% | -14.7x |
| Vanda Pharmaceuticals Inc.VNDA | $375.8M | — | 1.1x | -67.4% | — |
| Delcath Systems, Inc.DCTH | $372.5M | 138.0x | 3.3x | 2.4% | 327.0x |
| Perspective Therapeutics, Inc.CATX | $370.7M | -3.6x | 1.8x | -49.8% | -3.4x |
| Peer median | — | -5.8x | 2.3x | -36.4% | -5.1x |
Year-to-date ROI
LXEO since 1 January, against earlier years.
Historical volatility
LXEO's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -9309.2% |
| FY2023 | — |
| FY2024 | — |
| FY2025 | — |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $109.3M |
| Research and developmentResearch And Development | $63.8M |
| Selling, general and administrativeSelling General And Administration | $45.5M |
| Total expensesTotal Expenses | $109.3M |
| Operating incomeOperating Income | -$109.3M |
| Interest and other | |
| Pretax incomePretax Income | -$100.0M |
| TaxTax Provision | $0.00 |
| Net incomeNet Income | -$100.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $268.7M |
| Current assetsCurrent Assets | $188.4M |
| Non-current assetsTotal Non Current Assets | $80.3M |
| LiabilitiesTotal Liabilities Net Minority Interest | $22.0M |
| Current liabilitiesCurrent Liabilities | $16.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $5.2M |
| EquityTotal Equity Gross Minority Interest | $246.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$98.6M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$98.6M |
| Net income, continuing operationsNet Income From Continuing Operations | -$100.0M |
| Depreciation and amortisationDepreciation And Amortization | $2.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $2.1M |
| Depreciation | $2.1M |
| Amortization of securitiesAmortization Of Securities | $110.0k |
| Stock-based compensationStock Based Compensation | $12.1M |
| Operating gains and lossesOperating Gains Losses | -$3.4M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$3.4M |
| Change in working capitalChange In Working Capital | -$9.5M |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | -$90.3M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$90.3M |
| Capital expenditureCapital Expenditure | -$400.0k |
| Purchase of PP&EPurchase Of PPE | -$400.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$400.0k |
| Purchase of investmentsPurchase Of Investment | -$195.4M |
| Sale of investmentsSale Of Investment | $105.5M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$89.9M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | $216.8M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $216.8M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$530.0k |
| Net debt issuedNet Issuance Payments Of Debt | -$530.0k |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$530.0k |
| Net long-term debt issuedNet Long Term Debt Issuance | -$530.0k |
| Shares issuedIssuance Of Capital Stock | $234.0M |
| Common stock issuedCommon Stock Issuance | $234.0M |
| Net common stock issuedNet Common Stock Issuance | $234.0M |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $60.0k |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | -$16.8M |
| Change in cashChanges In Cash | $28.0M |
| Cash at the start of the yearBeginning Cash Position | $38.3M |
| Cash at the end of the yearEnd Cash Position | $66.3M |
| Free cash flowFree Cash Flow | -$99.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Lexeo Therapeutics, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read